Towards reinforcing adoptive cancer immunotherapy, a ‘Synthetic Immune Niche’ (SIN) strategy was recently developed by Adutler-Lieber et.al., based on the stimulation of T-cells by surfaces, coated with the chemokine C-C motif Ligand 21 (CCL21) and the Intercellular Adhesion Molecule 1 (ICAM-1) (20, 21). This evidence concerns the gene ICAM1 and cancer.